On November 9, 2021, Mekonos, Inc. closed the transaction. The company has raised $25,000,000 in the transaction co-led by new investors Reimagined Ventures, LLC, Fiscus Ventures, and PEAK6 Investments LLC. The transaction included participation from New institutional and strategic investors, including Section 32, LLC, Sands Capital Management, LLC, TDK Ventures, Inc., and the venture arm of Debiopharm International S.A., and previous investors, including Novartis AG, Good AI Capital LLC and Elementum Ventures. The company has received $24,979,834 from 23 investors pursuant to Regulation D.